NAGE

Niagen Bioscience, Inc. Common Stock

NAGE
Closed
$3.45
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

Niagen Bioscience, Inc. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. The company is headquartered in Los Angeles, California and currently employs 117 full-time employees. The company went IPO on 2007-06-25. Its segments include Consumer Products, Ingredients segment, Analytical Reference Standards and Services and Pharmaceuticals. The Consumer Products segment provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors. The ingredients segment develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen and pharmaceutical-grade Niagen, and supplies these ingredients as raw materials to the manufacturers of consumer products and outsourcing facilities. The Analytical Reference Standards and Services segment offer the supply of phytochemical reference standards and other research and development services. The Pharmaceutical segment focuses on the pharmaceutical development of its nicotinamide adenine dinucleotide (NAD) precursor portfolio for potential therapeutic applications in rare diseases.
Country

US

CEO

Mr. Robert Fried

IPO date

2007

Employees

117

ISIN

US1710774076

Key stats

Open

$3.47

Volume

646.01K

Market cap

$277.96M

Prev. close

$3.49

Impl / hst vl

-

Open interest

$0.00

$3.40

Day’s Range

$3.52

$3.18

52W Range

$6.87

Valuation

77
Valuation score
Undervalued
P/E
14.68
P/S
2.10
P/B
3.32
Current ratio
4.61
Debt / Equity
-0.81
ROE
25.38%
Gross margin
63.47%
Income growth
52.90%
FCF growth
-317.13

Analysts estimates

Consensus rating
Buy

The average rating from top 6 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$12.85
The top 7 analysts forecasts that 12-month price may increase by 272.52%, with a low of $10.10 and a high of $18.90
$10.10
Low
$12.85
Avg
$18.90
High
Current price

Earnings

Q1 ‘26 revenue
$31.47M
Q1 ‘26 net income
$6.32M
Revenue
Net income
Previous EPS
$0.07
Estimate EPS
$0.02
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply